Medlab Clinical Ltd operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Medlab Clinical Ltd with three other companies in this sector in AUSTRALIA : Cellmid Limited (2021 sales of 5.82 million Australian Dollars [US$4.24 million] of which 75% was Advangen Japan), Paradigm Biopharmaceuticals Ltd (8.94 million Australian Dollars [US$6.52 million] of which 100% was Research and development of pharmaceutic), and Exopharm Ltd (4.19 million Australian Dollars [US$3.05 million] ).

Sales Analysis. Medlab Clinical Ltd reported sales of A$6.69 million (US$4.88 million) for the fiscal year ending June of 2021. This represents an increase of 24.6% versus 2020, when the company's sales were A$5.37 million. Despite this increase, sales are still well below the level achieved in 2019, when Medlab Clinical Ltd reported sales of A$7.80 million. Sales of Corporate/ Other saw an increase that was more than double the company's growth rate: sales were up 4,759.4% in 2021, from A$76,142.00 to A$3.70 million. Medlab Clinical Ltd also saw significant increases in sales in Nutraceutical (up 70.4% to A$3.68 million) . Not all segments of Medlab Clinical Ltd experienced an increase in sales in 2021: sales of Pharmaceutical Research fell 79.1% to A$747,747.00 .